Highlights frameworks for early lung cancer detection pathways which intersect with bronchoscopic diagnostic procedures in underserved populations.
🎯 Background & Rationale
- Subpleural lesions: Subpleural lung lesions can be visualized clearly by conventional ultrasound, making it the guideline-recommended percutaneous approach.
- CT utilization: Despite ultrasound advantages, computed tomography remains widely used due to its ability to visualize deep central lesions and comprehensive chest views.
- Clinical gap: While contrast-enhanced ultrasound improves vascular visualization and lesion differentiation, no large randomized controlled trial has systematically compared contrast-enhanced ultrasound against conventional ultrasound and computed tomography for subpleural lung lesion biopsy.
👥 Study Design & Population
- Study type: This was a prospective, multicenter, open-label, analyst-blinded, parallel-group randomized controlled trial conducted across four major Chinese tertiary hospitals.
- Participants: A total of 2485 patients scheduled for percutaneous lung needle biopsy of subpleural lung lesions were randomized to ultrasound (n = 828), contrast-enhanced ultrasound (n = 829), or computed tomography (n = 828) groups.
- Baseline parity: Baseline demographics, lesion size, anatomic location, and malignant proportions (overall approximately 74% to 77%) were well-balanced across all three study arms.
📈 Methodology & Rigor
- Randomization scheme: Patients were randomized in a 1:1:1 ratio via a centralized, web-based, computer-generated system ensuring robust allocation concealment.
- Blinding measures: Operator allocation was revealed only immediately before the procedure; data collectors, statistical analysts, pathologists, and microbiologists remained blinded.
- Statistical rigor: Primary analyses were performed in the intention-to-treat population using multiple imputation for missing data, supplemented by per-protocol analyses and worst-case sensitivity models.
🔬 Key Findings [or Planned Endpoints]
- Diagnostic yield: Contrast-enhanced ultrasound achieved the highest diagnostic yield at 88.8% (736/829), outperforming computed tomography at 78.9% (653/828) and ultrasound at 76.0% (629/828) (chi-square = 49.046, P < 0.001).
- Diagnostic sensitivity: Overall disease sensitivity was highest with contrast-enhanced ultrasound at 86.1% (714/829), versus 74.3% (615/828) for computed tomography and 68.7% (569/828) for ultrasound (chi-square = 72.623, P < 0.001).
- Malignant subtypes: Contrast-enhanced ultrasound yielded superior sensitivity for malignant subtypes like adenocarcinoma and squamous cell carcinoma (91.8% vs 83.2% vs 75.2%, chi-square = 62.259, P < 0.001).
- Benign disorders: Contrast-enhanced ultrasound achieved superior sensitivity for specific benign disorders like tuberculosis and abscesses (69.9% vs 46.8% vs 47.1%, chi-square = 29.712, P < 0.001).
- Complication rates: The overall procedural complication rate was lowest in the contrast-enhanced ultrasound group at 4.6% (38/828), followed by ultrasound at 7.5% (60/802) and computed tomography at 15.8% (127/805) (chi-square = 65.322, P < 0.001).
⚖️ Critical Appraisal
- Internal validity: The trial benefits from a very large, well-powered sample size, multicenter design, robust allocation concealment, and blinded outcome assessment.
- Generalizability: Results are robust across multiple centers in China, though operator dependence in ultrasound and needle selection introduces minor institutional variability.
- Minor limitations: Simple randomization without site stratification was utilized, and secondary outcomes like core needle biopsy versus fine needle aspiration utilization varied by group.
💡 The Clinical Bottom Line
Contrast-enhanced ultrasound-guided percutaneous lung needle biopsy significantly improves diagnostic yield, malignant and benign disease-specific sensitivity, and procedural safety compared to conventional ultrasound and computed tomography guidance. For subpleural lung lesions, contrast-enhanced ultrasound should be adopted as an optimal standard technique to maximize tissue adequacy while minimizing complications.
Abstract
Keep reading
N opens the next oneDirectly impacts IP practice by highlighting the critical role of bronchoscopic sampling techniques in providing adequate tissue for molecular profiling.
Highlights the critical importance of obtaining adequate tissue via bronchoscopic biopsies for comprehensive molecular profiling.
Relevant to ablative therapies often managed or co-evaluated by interventional pulmonologists in the multidisciplinary management of lung malignancies.
Relevant for IP specialists involved in the bronchoscopic and image-guided tissue diagnosis and staging of apical lung masses.
Relevant to IP practices managing pulmonary nodules discovered during staging or diagnostic workups.